



SATELLITE SYMPOSIUM SUPPORTED BY NOVARTIS

08:00 – 10.00

Hall 3

DIVERSE MOLECULAR THERAPEUTIC STRATEGIES FOR HEMATOLOGIC MALIGNANCIES

Chair: O Ottmann (Johann Wolfgang Goethe Universität, Frankfurt, Germany)

08:00 – 08:10

■ **INTRODUCTION AND OBJECTIVES**

O Ottmann (Johann Wolfgang Goethe Universität, Frankfurt, Germany)

08:10 – 08:25

■ **MOLECULAR TARGETS IN HEMATOLOGIC MALIGNANCIES**

O Ottmann (Johann Wolfgang Goethe Universität, Frankfurt, Germany)

08:25 – 09:00

■ **CLINICAL PROMISE OF DEACETYLASE INHIBITION: EXPERIENCE WITH A PAN-DEACETYLASE INHIBITOR**

- Focus on Multiple Myeloma, Acute Myelogenous Leukemia (AML), Advanced Lymphoma, and Myelodysplastic Syndrome
- E Ocio (University of Salamanca, Salamanca, Spain)

09:00 – 09:25

■ **TARGETING KEY RESISTANCE MUTATIONS IN AML AND AGGRESSIVE SYSTEMIC MASTOCYTOSIS WITH NOVEL TYROSINE KINASE INHIBITORS**

C Thiede (Universitätsklinikum Carl Gustav Garus, Dresden, Germany)

09:25 – 09:50

■ **BROADENING THE CLINICAL ROLE OF MTOR INHIBITION – AN EMERGING THERAPEUTIC STRATEGY FOR LYMPHOMA**

P Johnston (Mayo Clinic, Rochester, MN, USA)

09:50 – 10:00

■ **QUESTION AND ANSWER SESSION**

O Ottmann (Johann Wolfgang Goethe Universität, Frankfurt, Germany)